Company Overview
| Location | Kyoto University Med-Pharm Collaboration Building #415, 46-29 Yoshida-Shimo-Adachi-cho, Sakyo-ku, Kyoto 606-8501, Japan [Map] |
|---|---|
| Management | Yasumich Hitoshi, M.D., Ph.D., CEO/CTO Ryosuke Gonotsubo, MBA, COO/CFO Shin Kaneko, M.D., PhD., Founder, Director Hiroyuki Ueno, Ph.D., Director |
| Established | August 24, 2015 |
| Shareholders | Kyoto University Innovation Capital Co., Ltd., Future Venture Capital Co., Ltd., Yasumichi Hitoshi, Shin Kaneko, Ryosuke Gonotsubo, and others |
| Founder | Yoshimoto Katsura, Professor emeritus, Kyoto University Shin Kaneko, Professor, Kyoto University |
What’s “Thyas”
- The organ where T cells learn how to recognize foreign antigens but not self, is called “Thymus”. Mature T cells show antigen specific target recognition, and the pronunciation of “as” is reminiscent of a Japanese word “tomorrow” or “future.” “Thyas” is a coined word made from “Thymus” & “as” (antigen specific and tomorrow), meaning “the place where next-gen T cell therapy is born.”
- Thyas is a genus of moths in the family Erebidae, and found mostly in Asia including Japan. Our company logomark is designed after Thyas, representing T cell receptor chains (center) and associated molecules (side). It is also an image of a dancing lady with Kimono fabricated in Kyoto.